Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This protocol describes a double-blind study to evaluate the safety and pharmacokinetics of
multiple IV doses of 1200 mg ORBACTIV (oritavancin) in healthy subjects.